Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised evaluation of low-dose cytosine arabinoside plus lenalidomide versus single-agent low-dose cytosine arabinoside in older patients with acute myeloid leukaemia: Results from the LI-1 trial.
Copland M, Ariti C, Thomas IF, Upton L, Sydenham M, Mehta P, Islam S, Kjeldsen L, Burnett AK, Hills RK, Russell N, Dennis M; UK NCRI AML Study Group. Copland M, et al. Among authors: russell n. Br J Haematol. 2024 Mar;204(3):871-876. doi: 10.1111/bjh.19220. Epub 2023 Nov 28. Br J Haematol. 2024. PMID: 38016651 Free article.
Outcomes following 50 mg versus 100 mg alemtuzumab in reduced-intensity conditioning stem cell transplants for acute myeloid leukaemia and poor risk myelodysplasia.
Tholouli E, Liakopoulou E, Greenfield HM, Shaw BE, Tauro S, Byrne JL, Dennis M, Burthem J, Lucas GS, Craddock C, Russell NH, Liu Yin JA. Tholouli E, et al. Br J Haematol. 2008 Jun;142(2):318-20. doi: 10.1111/j.1365-2141.2008.07184.x. Epub 2008 May 19. Br J Haematol. 2008. PMID: 18492100 Free article. No abstract available.
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Burnett AK, Milligan D, Goldstone A, Prentice A, McMullin MF, Dennis M, Sellwood E, Pallis M, Russell N, Hills RK, Wheatley K; United Kingdom National Cancer Research Institute Haematological Oncology Study Group. Burnett AK, et al. Among authors: russell n. Br J Haematol. 2009 May;145(3):318-32. doi: 10.1111/j.1365-2141.2009.07604.x. Epub 2009 Mar 8. Br J Haematol. 2009. PMID: 19291085 Free article. Clinical Trial.
European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy.
Burnett AK, Russell NH, Kell J, Dennis M, Milligan D, Paolini S, Yin J, Culligan D, Johnston P, Murphy J, McMullin MF, Hunter A, Das-Gupta E, Clark R, Carr R, Hills RK. Burnett AK, et al. J Clin Oncol. 2010 May 10;28(14):2389-95. doi: 10.1200/JCO.2009.26.4242. Epub 2010 Apr 12. J Clin Oncol. 2010. PMID: 20385984 Clinical Trial.
The addition of the farnesyl transferase inhibitor, tipifarnib, to low dose cytarabine does not improve outcome for older patients with AML.
Burnett AK, Russell NH, Culligan D, Cavanagh J, Kell J, Wheatley K, Virchis A, Hills RK, Milligan D; AML Working Group of the UK National Cancer Research Institute. Burnett AK, et al. Br J Haematol. 2012 Aug;158(4):519-22. doi: 10.1111/j.1365-2141.2012.09165.x. Epub 2012 May 29. Br J Haematol. 2012. PMID: 22639959 Free article. Clinical Trial.
1,159 results